6/5
07:08 am
avir
Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024 [Yahoo! Finance]
Medium
Report
Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024 [Yahoo! Finance]
6/5
07:00 am
avir
Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024
Medium
Report
Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024
5/29
07:00 am
avir
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
Neutral
Report
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
5/22
07:11 am
avir
Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024 [Yahoo! Finance]
Medium
Report
Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024 [Yahoo! Finance]
5/22
07:00 am
avir
Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024
Medium
Report
Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024
5/14
04:16 pm
avir
Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
5/14
04:05 pm
avir
Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
5/7
07:00 am
avir
Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024
Low
Report
Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024
4/29
07:13 am
avir
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024 [Yahoo! Finance]
Neutral
Report
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024 [Yahoo! Finance]
4/29
07:00 am
avir
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
Neutral
Report
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
4/22
09:11 am
avir
Global Dengue Pipeline Landscape Report 2024: Therapeutic Assessment and Drug Analysis of 20+ Drugs [Yahoo! Finance]
Low
Report
Global Dengue Pipeline Landscape Report 2024: Therapeutic Assessment and Drug Analysis of 20+ Drugs [Yahoo! Finance]
3/27
07:15 am
avir
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients [Yahoo! Finance]
Medium
Report
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients [Yahoo! Finance]
3/27
07:00 am
avir
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
Medium
Report
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients